Genetic and pharmacological screens converge in identifying FLIP, BCL2, and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10

Cancer Research

Volumn 75, Issue 8, 2015, Pages 1668-1674

  Allen, Joshua E ^a   Prabhu, Varun V ^a   Talekar, Mala ^a   Van Den Heuvel, A Pieter J ^a   Lim, Bora ^a   Dicker, David T ^a   Fritz, Jennifer L ^a   Beck, Adam ^b   El Deiry, Wafik S ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BORTEZOMIB; DACARBAZINE; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; HYDROXYUREA; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; ONC 201; PRALATREXATE; PROTEIN BCL 2; PROTEIN MCL 1; SORAFENIB; SURVIVIN; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VISMODEGIB; BCL2 PROTEIN, HUMAN; BIRC2 PROTEIN, HUMAN; BIRC3 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; INHIBITOR OF APOPTOSIS PROTEIN; MOLECULAR LIBRARY; TIC10 COMPOUND; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; DRUG RESISTANCE; GENETIC ASSOCIATION; GENETICS; HCT116 CELL LINE; HEPG2 CELL LINE; MOLECULAR LIBRARY; NUDE MOUSE; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENETIC ASSOCIATION STUDIES; HCT116 CELLS; HEP G2 CELLS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; SMALL MOLECULE LIBRARIES; UBIQUITIN-PROTEIN LIGASES;

EID: 84929220564     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2356     Document Type: Article

References (17)

1. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Sci Transl Med 2013;5:171ra17.
2. Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001;276:37879-86.
3. Ricci MS, Kim S-H, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80.
4. Therrien M, Michaud NR, Rubin GM, Morrison DK. KSR modulates signal propagation within the MAPK cascade. Genes Dev 1996;10:2684-95.
5. Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Res 2011;71:1883-92.
6. Engesaeter B, Engebraaten O, Florenes VA, Maelandsmo GM. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anti-cancer effects in melanoma. PLoS ONE 2012;7:e45492.
7. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-63.
8. Chen K-F, TaiW-T, Liu T-H, Huang H-P, Lin Y-C, Shiau C-W, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010;16:5189-99.
9. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 2010;9:742-50.
10. Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S, et al. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. Int J Oncol 2012;42:101-8.
11. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL Lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490-500.
12. Wang W, Gallant J-N, Katz SI, Dolloff NG, Smith CD, Abdulghani J, et al. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther 2011;12: 229-38.
13. Swers JS, Grinberg L, Wang L, Feng H, Lekstrom K, Carrasco R, et al. Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol Cancer Ther 2013;12:1235-44.
14. Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther 2012;11:2087-95.
15. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010;14:1091-108.
16. Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M, et al. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol 2011;178:1529-43.
17. Allen JE, El-Deiry WS. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology 2011;141: 430-4.